{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T12:10:14Z","timestamp":1780920614401,"version":"3.54.1"},"reference-count":22,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T00:00:00Z","timestamp":1771545600000},"content-version":"vor","delay-in-days":50,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100020473","name":"Badan Riset dan Inovasi Nasional","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020473","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100015690","name":"Padjadjaran University","doi-asserted-by":"publisher","award":["2064\/UN6.3.1\/PT.00\/2022"],"award-info":[{"award-number":["2064\/UN6.3.1\/PT.00\/2022"]}],"id":[{"id":"10.13039\/501100015690","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010447","name":"Kementerian Riset, Teknologi dan Pendidikan Tinggi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010447","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013375","name":"Universitas Sumatera Utara","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013375","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009509","name":"Kementerian Riset Teknologi Dan Pendidikan Tinggi Republik Indonesia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009509","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014563","name":"Universitas Andalas","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014563","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment and Research Communications"],"published-print":{"date-parts":[[2026]]},"DOI":"10.1016\/j.ctarc.2026.101152","type":"journal-article","created":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T23:40:56Z","timestamp":1771717256000},"page":"101152","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Preliminary evaluation of Chidamide in combination with novel [177Lu]Lu-DOTAGA-rituximab in rituximab-resistant Raji cells"],"prefix":"10.1016","volume":"47","author":[{"family":"Ridwansyah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5677-2569","authenticated-orcid":false,"given":"Arifudin","family":"Achmad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hendris","family":"Wongso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jauharul","family":"Ardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N. Elly","family":"Rosilawati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Hasan","family":"Bashari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Holis Abdul","family":"Holik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Achmad Hussein S.","family":"Kartamihardja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bethy Suryawathy","family":"Hernowo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctarc.2026.101152_bib0001","doi-asserted-by":"crossref","first-page":"821","DOI":"10.3390\/cancers17050821","article-title":"Current landscape and future directions in Cancer immunotherapy: therapies, trials, and challenges","volume":"17","author":"Bandara","year":"2025","journal-title":"Cancers. (Basel)"},{"key":"10.1016\/j.ctarc.2026.101152_bib0002","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1363102","article-title":"Advancements in cancer immunotherapies targeting CD20: from pioneering monoclonal antibodies to chimeric antigen receptor-modified T cells","volume":"15","author":"Dabkowska","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ctarc.2026.101152_bib0003","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.3390\/ijms23031501","article-title":"Molecular aspects of resistance to immunotherapies\u2014advances in understanding and management of diffuse large B-cell lymphoma","volume":"23","author":"Kusowska","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ctarc.2026.101152_bib0004","doi-asserted-by":"crossref","first-page":"5570","DOI":"10.3390\/cancers13215570","article-title":"Radioimmunotherapy in oncology: overview of the last decade clinical trials","volume":"13","author":"Rondon","year":"2021","journal-title":"Cancers. (Basel)"},{"key":"10.1016\/j.ctarc.2026.101152_bib0005","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.3324\/haematol.2019.243543","article-title":"The regulation and function of CD20: an \u201cenigma\u201d of B-cell biology and targeted therapy","volume":"105","author":"Pavlasova","year":"2020","journal-title":"Haematologica"},{"key":"10.1016\/j.ctarc.2026.101152_bib0006","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/s41419-019-2210-0","article-title":"Novel HDAC inhibitor Chidamide synergizes with rituximab to inhibit diffuse large B-cell lymphoma tumour growth by upregulating CD20","volume":"11","author":"Guan","year":"2020","journal-title":"Cell Death. Dis."},{"key":"10.1016\/j.ctarc.2026.101152_bib0007","doi-asserted-by":"crossref","first-page":"7834","DOI":"10.1002\/chem.201200132","article-title":"DOTAGA-anhydride: a valuable building block for the preparation of DOTA-like chelating agents","volume":"18","author":"Bernhard","year":"2012","journal-title":"Chem. Eur. J."},{"key":"10.1016\/j.ctarc.2026.101152_bib0008","doi-asserted-by":"crossref","first-page":"3093","DOI":"10.3390\/molecules29133093","article-title":"Tailoring fibroblast-activation protein targeting for theranostics: a comparative preclinical evaluation of the 68Ga- and 177Lu-labeled monomeric and dimeric fibroblast-activation protein inhibitors DOTA.SA.FAPi and DOTAGA.(SA.FAPi)2","volume":"29","author":"L\u00e4ppchen","year":"2024","journal-title":"Molecules."},{"key":"10.1016\/j.ctarc.2026.101152_bib0009","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/s40658-023-00592-1","article-title":"Radiation exposure assessment of nuclear medicine staff administering [177Lu]Lu-DOTA-TATE with active and passive dosimetry","volume":"10","author":"Riveira-Martin","year":"2023","journal-title":"EJNMMI. Phys."},{"key":"10.1016\/j.ctarc.2026.101152_bib0010","doi-asserted-by":"crossref","first-page":"2685","DOI":"10.1007\/s00259-025-07103-7","article-title":"Radiotheranostic landscape: a review of clinical and preclinical development","volume":"52","author":"Tran","year":"2025","journal-title":"Eur. J. Nucl. Med. Mol. ImAging"},{"key":"10.1016\/j.ctarc.2026.101152_bib0011","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1038\/s41419-021-04187-5","article-title":"Chidamide triggers BTG1-mediated autophagy and reverses the chemotherapy resistance in the relapsed\/refractory B-cell lymphoma","volume":"12","author":"Xue","year":"2021","journal-title":"Cell Death. Dis."},{"key":"10.1016\/j.ctarc.2026.101152_bib0012","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1182\/blood.2023022348","article-title":"Loss of CD20 expression as a mechanism of resistance to mosunetuzumab in relapsed\/refractory B-cell lymphomas","volume":"143","author":"Schuster","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.ctarc.2026.101152_bib0013","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.2967\/jnumed.112.115170","article-title":"Radioimmunotherapy with 177Lu-DOTA-Rituximab: final results of a phase I\/II study in 31 patients with relapsing follicular, mantle cell, and other indolent B-cell lymphomas","volume":"54","author":"Forrer","year":"2013","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.ctarc.2026.101152_bib0014","first-page":"544","article-title":"An approach for conjugation of 177Lu- DOTA-SCN- Rituximab (BioSim) & its evaluation for radioimmunotherapy of relapsed & refractory B-cell non Hodgkins lymphoma patients","volume":"139","author":"Thakral","year":"2014","journal-title":"Indian J. Med. Res."},{"key":"10.1016\/j.ctarc.2026.101152_bib0015","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/s10967-010-0676-4","article-title":"Development of 177Lu-DOTA-anti-CD20 for radioimmunotherapy","volume":"287","author":"Yousefnia","year":"2011","journal-title":"J. Radioanal. Nucl. Chem."},{"key":"10.1016\/j.ctarc.2026.101152_bib0016","doi-asserted-by":"crossref","first-page":"62","DOI":"10.2174\/1874471008666141215151253","article-title":"Standardization of procedures for the preparation of 177Lu- and 90Y-labeled DOTA-Rituximab based on the freeze-dried kit formulation","volume":"8","author":"Wojdowska","year":"2015","journal-title":"Curr. Radiopharm."},{"key":"10.1016\/j.ctarc.2026.101152_bib0017","unstructured":"Doha F.J., Rahmani S., Rikhtechi P., Rasaneh S., Sheikholislam Z., Shahhosseini S. Development of DOTA-Rituximab to be labeled with 90Y for radioimmunotherapy of B-cell non-hodgkin lymphoma. 2017 2017;16:619\u201329."},{"key":"10.1016\/j.ctarc.2026.101152_bib0018","first-page":"95","article-title":"Rituximab iodination procedure for radioiodinated Rituximab (131I-Rituximab) preparation","volume":"51","author":"Ramli","year":"2019","journal-title":"Maj Kedokt Bdg"},{"key":"10.1016\/j.ctarc.2026.101152_bib0019","first-page":"443","article-title":"A review of advances in the last decade on targeted cancer therapy using 177Lu: focusing on 177Lu produced by the direct neutron activation route","volume":"11","author":"Chakravarty","year":"2021","journal-title":"Am. J. Nucl. Med. Mol. ImAging"},{"key":"10.1016\/j.ctarc.2026.101152_bib0020","doi-asserted-by":"crossref","DOI":"10.20517\/cdr.2020.109","article-title":"Clinical significance of the loss of CD20 antigen on tumor cells in patients with relapsed or refractory follicular lymphoma","author":"Michot","year":"2021","journal-title":"Cancer Drug Resist."},{"key":"10.1016\/j.ctarc.2026.101152_bib0021","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2022.40.16_suppl.e19537","article-title":"CD20 and CD19 expression loss in relapsed or refractory b-cell non-hodgkin lymphoma: a retrospective cohort","volume":"40","author":"Marshalek","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ctarc.2026.101152_bib0022","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.tiv.2019.02.014","article-title":"Addressing systematic inconsistencies between in vitro and in vivo transcriptomic mode of action signatures","volume":"58","author":"McMullen","year":"2019","journal-title":"Toxicol. In. Vitro"}],"container-title":["Cancer Treatment and Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294226000638?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294226000638?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T11:39:29Z","timestamp":1780918769000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468294226000638"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":22,"alternative-id":["S2468294226000638"],"URL":"https:\/\/doi.org\/10.1016\/j.ctarc.2026.101152","relation":{},"ISSN":["2468-2942"],"issn-type":[{"value":"2468-2942","type":"print"}],"subject":[],"published":{"date-parts":[[2026]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Preliminary evaluation of Chidamide in combination with novel [177Lu]Lu-DOTAGA-rituximab in rituximab-resistant Raji cells","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment and Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctarc.2026.101152","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101152"}}